It is interesting to note that oxymetholone does exhibit some tendency to convert to dihydrotestosterone in the body, although this does not occur via the 5-alpha reductase enzyme. Oxymetholone is already a dihydrotestosterone-based steroid, so no such alteration can take place. Aside from the added c-17 alpha alkylation (discussed below), oxymetholone differs from DHT only by the addition of a 2-hydroxymethylene group. This grouping can be removed metabolically, reducing oxymetholone to the potent androgen 17alpha-methyl dihydrotestosterone (mestanolone). 387 There is little doubt that this biotransformation contributes at least on some level to the androgenic nature of this steroid. Note that since 5-alpha reductase is not involved, the relative androgenicity of oxymetholone is not affected by the concurrent use of finasteride or dutasteride.
Drugs such as Nolvedex bind to the oestrogen receptors , therefore reducing the effects of the heightened oestrogen in the body. Such drugs do nothing to reduce the amount of oestrogen in the body; they merely reduce its effects via competition for the receptors . If the user wishes to reduce the amount of oestrogen they should look to drugs such as proviron and anastrozole , which are known as anti-aromatases - . they lower the conversion of the steroid to oestrogen and therefore reduces the overall amount of oestrogen present.